Comprehensive correlative science findings from patients treated with AFM24 monotherapy indicate an activation of NK cells and their migration to the tumor
Initial signs of clinical activity and a well-managed safety profile with no dose-limiting toxicities were shown in preliminary data from the combination study investigating AFM24 administered in combination with the immune checkpoint inhibitor atezolizumab
Further data updates to be presented in poster sessions on November 10 and 11, 2022 and to be made available on Affimed’s website
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.